147 related articles for article (PubMed ID: 22875581)
1. Factors associated with reduced antituberculous serum drug concentrations in patients with HIV-TB coinfection.
Ahmed R; Cooper R; Foisy M; Der E; Kunimoto D
J Int Assoc Physicians AIDS Care (Chic); 2012; 11(5):273-6. PubMed ID: 22875581
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic drug monitoring of antimycobacterial drugs in patients with both tuberculosis and advanced human immunodeficiency virus infection.
Holland DP; Hamilton CD; Weintrob AC; Engemann JJ; Fortenberry ER; Peloquin CA; Stout JE
Pharmacotherapy; 2009 May; 29(5):503-10. PubMed ID: 19397460
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in HIV-infected Indian children.
Mukherjee A; Velpandian T; Singla M; Kanhiya K; Kabra SK; Lodha R
Int J Tuberc Lung Dis; 2016 May; 20(5):666-72. PubMed ID: 27084822
[TBL] [Abstract][Full Text] [Related]
4. Serum drug concentrations of INH and RMP predict 2-month sputum culture results in tuberculosis patients.
Mah A; Kharrat H; Ahmed R; Gao Z; Der E; Hansen E; Long R; Kunimoto D; Cooper R
Int J Tuberc Lung Dis; 2015 Feb; 19(2):210-5. PubMed ID: 25574921
[TBL] [Abstract][Full Text] [Related]
5. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.
Weiner M; Benator D; Burman W; Peloquin CA; Khan A; Vernon A; Jones B; Silva-Trigo C; Zhao Z; Hodge T;
Clin Infect Dis; 2005 May; 40(10):1481-91. PubMed ID: 15844071
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of the First-Line Antituberculosis Drugs in Ghanaian Children with Tuberculosis with or without HIV Coinfection.
Antwi S; Yang H; Enimil A; Sarfo AM; Gillani FS; Ansong D; Dompreh A; Orstin A; Opoku T; Bosomtwe D; Wiesner L; Norman J; Peloquin CA; Kwara A
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27855070
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment.
Bhatt NB; Barau C; Amin A; Baudin E; Meggi B; Silva C; Furlan V; Grinsztejn B; Barrail-Tran A; Bonnet M; Taburet AM;
Antimicrob Agents Chemother; 2014 Jun; 58(6):3182-90. PubMed ID: 24663014
[TBL] [Abstract][Full Text] [Related]
8. Cohort profile of a study on outcomes related to tuberculosis and antiretroviral drug concentrations in Uganda: design, methods and patient characteristics of the SOUTH study.
Sekaggya-Wiltshire C; Castelnuovo B; von Braun A; Musaazi J; Muller D; Buzibye A; Gutteck U; Henning L; Ledergerber B; Corti N; Lamorde M; Fehr J; Kambugu A
BMJ Open; 2017 Sep; 7(9):e014679. PubMed ID: 28928173
[TBL] [Abstract][Full Text] [Related]
9. Cure of tuberculosis despite serum concentrations of antituberculosis drugs below published reference ranges.
Meloni M; Corti N; Müller D; Henning L; Gutteck U; von Braun A; Weber R; Fehr J
Swiss Med Wkly; 2015; 145():w14223. PubMed ID: 26700218
[TBL] [Abstract][Full Text] [Related]
10. Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana.
Tappero JW; Bradford WZ; Agerton TB; Hopewell P; Reingold AL; Lockman S; Oyewo A; Talbot EA; Kenyon TA; Moeti TL; Moffat HJ; Peloquin CA
Clin Infect Dis; 2005 Aug; 41(4):461-9. PubMed ID: 16028152
[TBL] [Abstract][Full Text] [Related]
11. Anti-tuberculosis drug concentrations in tuberculosis patients with and without diabetes mellitus.
Kumar AK; Chandrasekaran V; Kannan T; Murali AL; Lavanya J; Sudha V; Swaminathan S; Ramachandran G
Eur J Clin Pharmacol; 2017 Jan; 73(1):65-70. PubMed ID: 27651240
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients.
Rockwood N; Meintjes G; Chirehwa M; Wiesner L; McIlleron H; Wilkinson RJ; Denti P
Antimicrob Agents Chemother; 2016 Oct; 60(10):6050-9. PubMed ID: 27480859
[TBL] [Abstract][Full Text] [Related]
13. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000.
Li J; Munsiff SS; Driver CR; Sackoff J
Clin Infect Dis; 2005 Jul; 41(1):83-91. PubMed ID: 15937767
[TBL] [Abstract][Full Text] [Related]
14. Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection.
Benator DA; Weiner MH; Burman WJ; Vernon AA; Zhao ZA; Khan AE; Jones BE; Sandman L; Engle M; Silva-Trigo C; Hsyu PH; Becker MI; Peloquin CA;
Pharmacotherapy; 2007 Jun; 27(6):793-800. PubMed ID: 17542762
[TBL] [Abstract][Full Text] [Related]
15. The Use of Therapeutic Drug Monitoring in Complex Antituberculous and Antiretroviral Drug Dosing in HIV/Tuberculosis-Coinfected Patients.
Newman M; Foisy MM; Ahmed RA
J Int Assoc Provid AIDS Care; 2015; 14(4):295-9. PubMed ID: 25425639
[TBL] [Abstract][Full Text] [Related]
16. ISONIAZID AND RIFAMPIN PHARMACOKINETICS IN TWO ASIAN ELEPHANTS (ELEPHAS MAXIMUS) INFECTED WITH MYCOBACTERIUM TUBERCULOSIS.
Egelund EF; Isaza R; Alsultan A; Peloquin CA
J Zoo Wildl Med; 2016 Sep; 47(3):868-871. PubMed ID: 27691967
[TBL] [Abstract][Full Text] [Related]
17. The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis.
Perlman DC; Segal Y; Rosenkranz S; Rainey PM; Remmel RP; Salomon N; Hafner R; Peloquin CA;
Clin Infect Dis; 2005 Dec; 41(11):1638-47. PubMed ID: 16267738
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic drug monitoring of isoniazid and rifampicin during anti-tuberculosis treatment in Auckland, New Zealand.
Maze MJ; Paynter J; Chiu W; Hu R; Nisbet M; Lewis C
Int J Tuberc Lung Dis; 2016 Jul; 20(7):955-60. PubMed ID: 27287650
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of first-line antituberculosis drugs in HIV-infected children with tuberculosis treated with intermittent regimens in India.
Ramachandran G; Kumar AK; Bhavani PK; Kannan T; Kumar SR; Gangadevi NP; Banurekha VV; Sekar L; Ravichandran N; Mathevan G; Sanjeeva GN; Dayal R; Swaminathan S
Antimicrob Agents Chemother; 2015 Feb; 59(2):1162-7. PubMed ID: 25487804
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
